 |
 |
 |
|
|
 |
| ZYMOGENETICS
BOARD OF DIRECTORS |
 |
Bruce L.A. Carter, Ph.D.
Dr.
Carter was appointed Chairman of the Board
in April 2005. Dr.
Carter has been ZymoGenetics' Chief
Executive Officer since April 1998. Dr.
Carter first joined ZymoGenetics in 1986
as Vice President of Research and Development.
In 1994, he was chosen as Corporate Executive
Vice President and Chief Scientific Officer
for Novo Nordisk A/S, the former parent
company of ZymoGenetics. He was elected
to the board of ZymoGenetics in 1987 and
was appointed president of the company in 1998. Dr.
Carter led the negotiations that established
ZymoGenetics as an independent company
from Novo Nordisk in 2000. Dr. Carter
held various positions of increasing responsibility
at G.D. Searle & Co., Ltd. from 1982
to 1986 and was a Lecturer at Trinity
College , University of Dublin from 1975
to 1982. Dr. Carter received a B.Sc. with
Honors in Botany from the University of
Nottingham, England, and a Ph.D. in Microbiology
from Queen Elizabeth College , University
of London .
|
 |
James A. Harper
James A. Harper was appointed as a director
in July 2004. Mr. Harper has thirty years
of global marketing, operations and strategic
experience in the pharmaceutical and medical
device industries, and recently retired
from the post of Group Vice President of
Global Marketing and Sales at Eli Lilly
and Company. Mr. Harper currently is also
the Vice Chair of the Board of the American
Diabetes Association Research Foundation.
Mr. Harper holds an M.B.A. from the Wharton
School in Marketing/Finance and a B.A. from
Vanderbilt University in Biology. |
 |
Judith A. Hemberger, Ph.D.
Judith Hemberger, Ph.D., was appointed as
a director in March 2006. She has over 25
years of global pharmaceutical and biotech
industry experience. Dr. Hemberger was a
founder of Pharmion Corporation and served
as Executive Vice President and Chief Operating
Officer from 2000 to 2006. Prior to this,
Dr. Hemberger served as a consultant to
healthcare companies and worked for Marion
Laboratories, Marion Merrell Dow and Hoechst
Marion Roussel, where she was responsible
for leading strategic functions such as
global medical affairs, global regulatory
affairs and commercial development. Dr.
Hemberger received a B.S. in biology and
chemistry from Mount St. Scholastica College
(St. Benedictine College), a Ph. D. in Pharmacology
from the University of Missouri and an M.B.A
from Rockhurst College. |
 |
David I. Hirsh, Ph.D.
Dr. Hirsh has served as a director since
November 2000. Dr. Hirsh is Executive Vice
President of Research at Columbia University,
where he served as the Robert Wood Johnson,
Jr. Professor and Chairman of the Department
of Biochemistry and Molecular Biophysics
at the College of Physicians and Surgeons
of Columbia University since 1990. From
1984 to 1990, he served as Executive Vice
President of Research at Synergen, Inc.,
a biotechnology company. From 1971 to 1985,
he served as a Professor at the University
of Colorado. Dr. Hirsh received a B.A. in
Biology from Reed College and a Ph.D. in
Biochemistry from Rockefeller University. |
 |
Jonathan S. Leff
Mr. Leff has served as a director since
November 2000. Since January 2000, Mr. Leff
has served as a General Partner of Warburg,
Pincus & Co., which is the Managing Partner
of Warburg Pincus LLC, and as a Managing
Director of Warburg Pincus LLC, a private
equity investment firm. From January 1999
to December 1999, Mr. Leff served as a Vice
President of Warburg Pincus LLC and as an
Associate from July 1996 to December 1998.
Mr. Leff currently serves as a director
of InterMune, Inc. and Transkaryotic Therapies,
Inc. Mr. Leff received a B.A. in Government
from Harvard College and an M.B.A. from
Stanford University. |
 |
David
H. MacCallum
Mr.
MacCallum is Managing Director of Outer
Islands Capital, a hedge fund specializing
in health care investments. He served
as Global Head of Health Care investment
banking for Salomon Smith Barney and formed
the Life Sciences group at UBS Securities,
where he was Managing Director and Global
Head of Life Sciences. Prior to that,
Mr. MacCallum built the health care practice
at Hambrecht & Quist, an investment
banking firm, where he was Head of Health
Care and Co-Head of Investment Banking.
Mr. MacCallum received an A. B. degree
from Brown University and an M.B.A. degree
from New York University. He holds the
Chartered Financial Analyst designation.
|
 |
Kurt Anker Nielsen
Mr. Nielsen has served as a director since
June 1997. From December 2000 to September,
2003, when he retired, Mr. Nielsen served
as Co-Chief Executive Officer of Novo A/S.
Mr. Nielsen held numerous positions within
the Novo Nordisk organization since joining
Novo Nordisk in 1974, including Deputy Chief
Executive Officer, Chief Financial Officer,
Executive Vice President of Corporate Finance,
Vice President of Corporate Planning and
Communications, and Head of the Corporate
Planning Department. Prior to joining Novo
Nordisk, Mr. Nielsen served as a management
consultant at Booz, Allen and Hamilton of
Scandinavia. He also served as a business
economist at Carlsberg A/S in Denmark. Mr.
Nielsen serves as a director of Coloplast
A/S, DakoCytomation A/S, Novo Nordisk A/S
and Novozymes A/S. Mr. Nielsen received
a B.A in Economics and an M.A. in Commerce
from the Copenhagen Business School. |
 |
Edward E. Penhoet, Ph.D.
Dr. Penhoet has served as a director since
May 2000. Since September 2000, Dr. Penhoet has been a director of the Alta Biopharma II Fund at Alta Partners, a venture capital firm. Dr. Penhoet is past President of the Gordon and Betty Moore Foundation, where he served since 2002 as Chief Program Officer, Science and Higher Education. He served as Dean
of the School of Public Health at the University
of California, Berkeley from July 1998 to
July 2002. From May 1998 to February 2001,
he served as Vice Chairman of the board
of Chiron Corporation, a biotechnology company,
which he co-founded in 1981. From 1981 to
May 1998, he served as President, Chief
Executive Officer and a director of Chiron.
From 1971 to 1981, he was a faculty member
in the Department of Biochemistry at the
University of California, Berkeley. Dr.
Penhoet currently serves as a director of
Chiron and several privately held companies.
Dr. Penhoet received a B.A. in Biology from
Stanford University and a Ph.D. in Biochemistry
from the University of Washington. |
 |
Lars Rebien Sørensen
Mr. Sørensen has served as a director since January 1996. Lars Rebien Sørensen is President and Chief Executive Officer of Novo Nordisk A/S. He joined Novo Nordisk’s Enzymes Marketing in 1982. Mr Sørensen was appointed member of Corporate Management in May 1994 and given special responsibility within Corporate Management for Health Care in December 1994. He was appointed president and CEO in November 2000. Mr Sørensen is a member of the Board of DONG Energy A/S, Denmark, as well as a member of the Bertelsmann AG Supervisory Board, Germany. Mr Sørensen received the French award Chevalier de l'Ordre National de la Légion d'Honneur in 2005. Mr Sørensen has an MSc in Forestry from The Royal Veterinary and Agricultural University in Denmark, and a BSc in International Economics from the Copenhagen Business School, Denmark.
|
Corporate
Governance
|
|
|
|
Back to top
